What SEC filings does Indivior Pharmaceuticals, Inc. submit to the SEC?

Indivior Pharmaceuticals, Inc. (INDV) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about INDV?

A Form 4 for INDV discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Indivior Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for INDV?

The 10-K is Indivior Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all INDV SEC filings directly on EDGAR?

You can view all historical Indivior Pharmaceuticals, Inc. filings on the SEC EDGAR company page for INDV. Each filing card on this page links directly to the original SEC document.

How often does Indivior Pharmaceuticals, Inc. file with the SEC?

Indivior Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling INDV shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

INDV SEC Filing News — Indivior Pharmaceuticals, Inc.

Latest SEC filings for Indivior Pharmaceuticals, Inc. (INDV) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sub…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $4.0B CIK: 1625297

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for INDV currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 2 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

INDV Filing Activity Snapshot 2026-05-14 — 2026-10-15

Insider Transactions (Form 4)

2 buys vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.36M

Preblick Ryan (Chief Financial Officer) · 2026-06-10

36,000 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Indivior Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 3 open-market sale, 2 compensation award, 2 open-market purchase and 1 option exercise. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Open-market purchase Insider Buying 2026-08-27

INDV insider Anderson Woodrow D (Chief Accounting Officer) bought 1,500 shares (~$53.5K)

Anderson Woodrow D, listed as Chief Accounting Officer at Indivior Pharmaceuticals, Inc., reported an open-market purchase of 1,500 INDV shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,500	$35.69	$53.5K

Filing: Form 4 (Insider Transaction) Insider: Anderson Woodrow D (Chief Accounting Officer) Shares: 1,500 Est. Value: $53.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-05

INDV insider Anderson Woodrow D (Chief Accounting Officer) bought 1,500 shares (~$54.4K)

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,500	$36.28	$54.4K

Filing: Form 4 (Insider Transaction) Insider: Anderson Woodrow D (Chief Accounting Officer) Shares: 1,500 Est. Value: $54.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-13

INDV insider Heidbreder Christian (Chief Scientific Officer) sold 18,586 shares (~$764.6K)

Heidbreder Christian, listed as Chief Scientific Officer at Indivior Pharmaceuticals, Inc., reported an open-market sale of 18,586 INDV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	18,586	$41.14	$764.6K

Filing: Form 4 (Insider Transaction) Insider: Heidbreder Christian (Chief Scientific Officer) Shares: 18,586 Est. Value: $764.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-06-23

INDV insider Form 4 filed for equity award, exercise, or tax withholding

Ciaffoni Joseph (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,266,903	—	—
`F`	Tax withholding on vested shares	612,549	$38.32	$23.47M
`M`	Option exercise derivative · Performance Stock Units	1,266,903	—	—

Filing: Form 4 (Insider Transaction) Insider: Ciaffoni Joseph (Director, Chief Executive Officer) Shares: 1,879,452

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-12

INDV insider Heidbreder Christian (Chief Scientific Officer) sold 18,586 shares (~$707.4K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	18,586	$38.06	$707.4K

Filing: Form 4 (Insider Transaction) Insider: Heidbreder Christian (Chief Scientific Officer) Shares: 18,586 Est. Value: $707.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-10

INDV insider Preblick Ryan (Chief Financial Officer) sold 36,000 shares (~$1.36M)

Preblick Ryan, listed as Chief Financial Officer at Indivior Pharmaceuticals, Inc., reported an open-market sale of 36,000 INDV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	36,000	$37.70	$1.36M

Filing: Form 4 (Insider Transaction) Insider: Preblick Ryan (Chief Financial Officer) Shares: 36,000 Est. Value: $1.36M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-14

INDV insider Form 4 filed for equity award, exercise, or tax withholding

Thompson Juliet (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	1,117	$38.28	$42.8K
`A`	Compensation award	6,518	—	—

Filing: Form 4 (Insider Transaction) Insider: Thompson Juliet (Director) Shares: 7,635

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-14

INDV insider Form 4 filed for equity award, exercise, or tax withholding

Humphreys Keith (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,518	—	—

Filing: Form 4 (Insider Transaction) Insider: Humphreys Keith (Director) Shares: 6,518

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Indivior Pharmaceuticals, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-07-10

INDV Form 144 filed for proposed insider sale by Heidbreder Christian (18,586 shares) ~$764.6K

Heidbreder Christian filed a Form 144 with the SEC indicating intent to sell INDV (Indivior Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Heidbreder Christian Shares: 18,586 Est. Value: $764.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-11

INDV Form 144 filed for proposed insider sale by Heidbreder Christian (18,586 shares) ~$707.4K

Filing: Form 144 (Proposed Sale Notice) Insider: Heidbreder Christian Shares: 18,586 Est. Value: $707.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-08

INDV Form 144 filed for proposed insider sale by Preblick Ryan (36,000 shares) ~$1.36M

Preblick Ryan filed a Form 144 with the SEC indicating intent to sell INDV (Indivior Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Preblick Ryan Shares: 36,000 Est. Value: $1.36M

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Indivior Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-15

INDV filed 8-K — material company event

Indivior Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.